文献速递胸部肿瘤

NSCLC中MTAP缺失与共存致癌驱动突变(含EGFR)的临床意义

Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC.
PubMed 文献 · J Thorac Oncol · 2025-11-17

本研究基于4926例NSCLC肿瘤的MSK-IMPACT测序数据,发现10%存在MTAP缺失,其中83%的IV期MTAP缺失肿瘤共存致癌驱动突变(48%为EGFR突变)。基线MTAP缺失与奥希替尼单药停药时间缩短相关,但不影响总生存;获得性MTAP缺失见于13%的奥希替尼耐药后样本,1例MTAP缺失伴EGFR突变患者对PRMT5抑制剂单药部分缓解。

要点

  • NSCLC中MTAP缺失发生率为10%,IV期病例中83%共存致癌驱动突变。
  • 基线MTAP缺失与奥希替尼单药停药时间缩短相关,但不影响总生存。
  • 奥希替尼耐药后13%出现获得性MTAP缺失,PRMT5抑制剂显示潜在活性。

核心结论

  • MTAP缺失在NSCLC中频繁与致癌驱动突变共存,并可在奥希替尼耐药时获得。
  • 一例致癌驱动阳性伴MTAP缺失的NSCLC患者对PRMT5抑制剂单药部分缓解。

研究设计与样本

  • 基于MSK-IMPACT下一代测序面板分析4926例NSCLC肿瘤,采用拷贝数方法评估MTAP缺失。

主要发现

  • 475/4926(10%)NSCLC肿瘤存在MTAP缺失。
  • 258例IV期MTAP缺失NSCLC中,214例(83%)共存致癌驱动突变,其中123例(48%)为EGFR突变。
  • 基线MTAP缺失与奥希替尼单药停药时间缩短相关(19.0 vs 24.9个月,HR 1.8,CI 1.02-3.15,p=0.01)。
  • MTAP缺失对总生存无统计学显著影响(38.4 vs 40.5个月,HR 1.7,CI 0.8-3.6,p=0.1)。
  • 69例奥希替尼耐药配对组织样本中,9例(13%)检出获得性MTAP缺失。

临床怎么用

  • 对NSCLC进行MTAP缺失检测可能有助于识别奥希替尼疗效较差的人群。
  • MTAP缺失伴致癌驱动突变患者可考虑PRMT5或MAT2A抑制剂临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Methylthioadenosine phosphorylase (MTAP) deletions (dels) occur with CDKN2A dels in a subset of NSCLCs. These deletions have been associated with inferior survival in several tumor types, and they may be targetable by PRMT5 and MAT2A inhibitors through synthetic lethality. Their co-occurrence with oncogenic drivers including EGFR is underexplored. METHODS: We analyzed 4926 NSCLC tumors sequenced with MSK-IMPACT, a next-generation sequencing panel, and evaluated the incidence of MTAP dels with a copy number-based approach. RESULTS: Of 4926 NSCLC tumors, 475 (10%) harbored an MTAP del. Among 258 stage IV MTAP-del NSCLC tumors, 214 (83%) also had a co-occurring oncogenic driver alteration, including 123 (48%) with EGFR mutations. Baseline MTAP del was associated with shorter time to osimertinib monotherapy discontinuation (19.0 versus 24.9 mo, hazard ratio 1.8, confidence interval 1.02-3.15, p = 0.01) but did not statistically significantly affect overall survival (38.4 versus 40.5 mo, hazard ratio 1.7, CI 0.8-3.6, p = 0.1). In patients who developed resistance to osimertinib with paired pre- and post-treatment tissue samples, acquired MTAP del was identified in nine of 69 patients (13%). A heavily pretreated patient with metastatic EGFR-mutant, MTAP-del NSCLC had a confirmed partial response to treatment with PRMT5 inhibitor monotherapy (BMS-986504). CONCLUSIONS: MTAP dels frequently co-occur with oncogenic driver alterations and can develop at time of osimertinib resistance. A patient with oncogenic driver-positive, MTAP-del NSCLC had a partial response to PRMT5 inhibitor treatment. This work could inform future trials of PRMT5 and MAT2A inhibitors.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ross JS, Thummalapalli R, Febres-Aldana CA, et al. Clinical Significance of MTAP Deletions and Their Overlap With Concurrent Oncogenic Driver Alterations Including EGFR in NSCLC. J Thorac Oncol. 2025. PMID: 41260457. doi:10.1016/j.jtho.2025.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。